Contrary to the belief of those outside manufacturing, establishing a bioprocess is not a one-time task. The inherent unpredictability of biology means things will inevitably go wrong even in the most controlled environments, making it a continuous and difficult challenge.
By isolating pre-placental tissue from ectopic pregnancies—which are non-viable and routinely discarded—it's possible to source the earliest stem cells without the ethical dilemmas associated with embryonic stem cell research from IVF clinics.
The HLAG protein on placental tissue acts as a natural "off-switch" for the maternal immune system, preventing rejection of the embryo. This inherent immune privilege makes these cells ideal for allogeneic "off-the-shelf" therapies that can be given to any patient without requiring a genetic match.
Unlike immortal human embryonic stem cells, which carry the risk of uncontrolled growth similar to cancer, naturally senescent cells are programmed to stop dividing after a set number of doublings. This finite lifespan provides a critical built-in safety feature, reducing regulatory and clinical concerns.
A key early strategy was to avoid giving unique stem cells to academic researchers. This prevented universities from filing their own patents on the technology, which would have created a costly "thicket" of IP that the company would later need to license back to commercialize its own product.
Early-stage stem cells offer massive scalability. Due to their high capacity for population doubling (up to 85 times), a single donor's cells can be expanded to produce enough therapeutic material to treat a virtually unlimited number of patients, solving a key manufacturing bottleneck in cell therapy.